乳腺癌的发病机制及临床治疗的研究进展

季 天培1, 王 振常2
1、广西中医药大学附属国际壮医医院
2、广西中医药大学基础医学院

摘要


乳腺癌作为全球女性健康的第二大威胁，其研究进展备受瞩目。本文深入探讨乳腺癌发病机制，涵盖遗传
因素、基因突变、激素水平及不良生活方式等多方面，剖析其发病根源。同时，全面阐述乳腺癌治疗临床研究新进
展，涉及手术、放疗、化疗及内分泌治疗等，旨在为临床治疗决策提供科学依据，助力改善患者预后，延长生存期，
提高生活质量。

关键词


乳腺癌；发病机制；治疗；进展

全文:

PDF


参考


[1]Global Burden of Disease Cancer Collaboration.

Global, Regional, and National Cancer Incidence, Mortality,

Years of Life Lost, Years Lived With Disability, and

Disability-Adjusted Life-years for 32 Cancer Groups,1990to

2015. JAMA Oncol. 2017 Apr 1;3(4):524-548.

[2]Möller S, Mucci LA, Harris JR, Scheike T, Holst K,

Halekoh U, Adami HO, Czene K, Christensen K, Holm NV,

Pukkala E, Skytthe A, Kaprio J, Hjelmborg JB. The Heritability

of Breast Cancer among Women in the Nordic Twin Study of

Cancer. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):145-

50. doi: 10.1158/1055-9965.EPI-15-0913.

[3]Sampson JN, Wheeler WA, Yeager M, et al. Analysis

of Heritability and Shared Heritability Based on GenomeWide Association Studies for Thirteen Cancer Types. J Natl

Cancer Inst. 2015 Oct 12;107(12):djv279. doi: 10.1093/jnci/

djv279. Erratum in: J Natl Cancer Inst. 2016 Apr;108(4).

[4]Severi G, Southey MC, English DR, et al.

Epigenome-wide methylation in DNA from peripheral blood

as a marker of risk for breast cancer. Breast Cancer Res Treat.

2014 Dec;148(3):665-73.

[5]Yang Y, Wu L, Shu XO, et al. Genetically Predicted

Levels of DNA Methylation Biomarkers and Breast Cancer

Risk: Data From 228 951 Women of European Descent. J

Natl Cancer Inst. 2020 Mar 1;112(3):295-304.

[6]Allott EH, Hursting SD. Obesity and cancer:

mechanistic insights from transdisciplinary studies. Endocr

Relat Cancer. 2015 Dec;22(6):R365-86.

[7]Zeitzer JM, Nouriani B, Rissling MB, Sledge GW,

Kaplan KA, Aasly L, Palesh O, Jo B, Neri E, Dhabhar FS,

Spiegel D. Aberrant nocturnal cortisol and disease progression

in women with breast cancer. Breast Cancer Res Treat. 2016

Jul;158(1):43-50.

[8]Collaborative Group on Hormonal Factors in Breast

Cancer. Type and timing of menopausal hormone therapy

and breast cancer risk: individual participant meta-analysis of

the worldwide epidemiological evidence. Lancet. 2019 Sep

28;394(10204):1159-1168.

[9]North American Menopause Society. The 2012

hormone therapy position statement of: The North American

Menopause Society. Menopause. 2012 Mar;19(3):257-71.

[10]Cottet V, Touvier M, Fournier A, Touillaud

MS, Lafay L, Clavel-Chapelon F, Boutron-Ruault MC.

Postmenopausal breast cancer risk and dietary patterns in the

E3N-EPIC prospective cohort study. Am J Epidemiol. 2009

Nov 15;170(10):1257-67.

[11]Castelló A, Pollán M, Buijsse B, Ruiz A, Casas AM,

Baena-Cañada JM, Lope V, Antolín S, Ramos M, Muñoz

M, Lluch A, de Juan-Ferré A, Jara C, Jimeno MA, Rosado

P, Díaz E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque

J, Boeing H, Martín M; GEICAM researchers. Spanish

Mediterranean diet and other dietary patterns and breast

cancer risk: case-control EpiGEICAM study. Br J Cancer.

2014 Sep 23;111(7):1454-62.

[12]Hirko KA, Willett WC, Hankinson SE, Rosner BA,

Beck AH, Tamimi RM, Eliassen AH. Healthy dietary patterns

and risk of breast cancer by molecular subtype. Breast Cancer

Res Treat. 2016 Feb;155(3):579-88.

[13]McTiernan A, Friedenreich CM, Katzmarzyk PT,

Powell KE, Macko R, Buchner D, Pescatello LS, BloodgoodB, Tennant B, Vaux-Bjerke A, George SM, Troiano RP,

Piercy KL; 2018 PHYSICAL ACTIVITY GUIDELINES

ADVISORY COMMITTEE*. Physical Activity in Cancer

Prevention and Survival: A Systematic Review. Med Sci

Sports Exerc. 2019 Jun;51(6):1252-1261.

[14]Ibrahim EM, Al-Homaidh A. Physical activity

and survival after breast cancer diagnosis: meta-analysis of

published studies. Med Oncol. 2011 Sep;28(3):753-65.

[15]Stick LB, Yu J, Maraldo MV, Aznar MC, Pedersen

AN, Bentzen SM, Vogelius IR. Joint Estimation of Cardiac

Toxicity and Recurrence Risks After Comprehensive Nodal

Photon Versus Proton Therapy for Breast Cancer. Int J Radiat

Oncol Biol Phys. 2017 Mar 15;97(4):754-761.

[16]Tanaka S, Iwamoto M, Kimura K, Matsunami N,

Morishima H, Yoshidome K, Nomura T, Morimoto T,

Yamamoto D, Tsubota Y, Kobayashi T, Uchiyama K. Phase

II Study of Neoadjuvant Anthracycline-Based Regimens

Combined With Nanoparticle Albumin-Bound Paclitaxel and

Trastuzumab for Human Epidermal Growth Factor Receptor

2-Positive Operable Breast Cancer. Clin Breast Cancer. 2015

Jun;15(3):191-6.

[17]Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE

Jr, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N. Prognosis

after ipsilateral breast tumor recurrence and locoregional

recurrences in five National Surgical Adjuvant Breast and

Bowel Project node-positive adjuvant breast cancer trials. J

Clin Oncol. 2006 May 1;24(13):2028-37.

[18]Donker M, van Tienhoven G, Straver ME, Meijnen

P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg

AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle

HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez

NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj

M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P,

Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ.

Radiotherapy or surgery of the axilla after a positive sentinel

node in breast cancer (EORTC 10981-22023 AMAROS): a

randomised, multicentre, open-label, phase 3 non-inferiority

trial. Lancet Oncol. 2014 Nov;15(12):1303-10.

[19]Early Breast Cancer Trialists' Collaborative Group

(EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter

D, Darby S, McGale P, Pan HC, Taylor C, Wang YC,

Dowsett M, Ingle J, Peto R. Relevance of breast cancer

hormone receptors and other factors to the efficacy of adjuvant

tamoxifen: patient-level meta-analysis of randomised trials.

Lancet. 2011 Aug 27;378(9793):771-84.

[20]Bidard FC, Kaklamani VG, Neven P, Streich G,

Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH,

Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon

PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E,

Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G,

Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant

(oral selective estrogen receptor degrader) Versus Standard

Endocrine Therapy for Estrogen Receptor-Positive, Human

Epidermal Growth Factor Receptor 2-Negative Advanced

Breast Cancer: Results From the Randomized Phase III

EMERALD Trial. J Clin Oncol. 2022 Oct 1;40(28):3246-3256.


Refbacks

  • 当前没有refback。